8-K: Immunome Stockholders Re-Elect Directors and Ratify Auditor at 2025 Annual Meeting

Immunome, Inc. announced the successful election of two Class II Directors and the overwhelming ratification of Ernst & Young LLP as its independent auditor at its 2025 Annual Meeting of Stockholders.

Summary

• Immunome, Inc. held its 2025 Annual Meeting of Stockholders on June 10, 2025.
• As of the record date, April 21, 2025, 87,011,822 shares of common stock were outstanding and entitled to vote at the Annual Meeting.
• Stockholders elected Isaac Barchas and Jean-Jacques Bienaim as Class II Directors, each to serve until the Company's 2028 Annual Meeting of Stockholders.
• Isaac Barchas received 46,329,807 votes For, 15,249,792 votes Withheld, and 14,740,497 Broker Non-Votes.
• Jean-Jacques Bienaim received 47,144,944 votes For, 14,434,655 votes Withheld, and 14,740,497 Broker Non-Votes.
• Stockholders ratified the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025.
• The ratification of Ernst & Young LLP received 76,259,572 votes For, 15,957 votes Against, and 44,567 Abstentions.

Sentiment

Score: 7

Explanation: The successful election of directors and ratification of the auditor indicate stable corporate governance and shareholder support for key operational aspects, which is generally positive. The presence of 'Withheld' votes for directors, while not preventing election, slightly tempers the overall positive sentiment.

Positives

• The company successfully elected its proposed Class II Directors, indicating shareholder support for the current board composition and strategic direction.
• The selection of Ernst & Young LLP as the independent auditor was overwhelmingly ratified with 76,259,572 votes For, demonstrating strong shareholder confidence in the company's financial oversight and reporting.

Negatives

• A notable number of votes were 'Withheld' for both director candidates (15,249,792 for Isaac Barchas and 14,434,655 for Jean-Jacques Bienaim), which, while not preventing their election, suggests some level of shareholder dissent or abstention from active support.

Future Outlook

The document does not provide specific forward-looking statements or guidance beyond the terms of service for the elected directors and the ratified auditor.

Management Comments

• "Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized." (Signed by Max Rosett, Chief Financial Officer)

Industry Context

This filing is a standard corporate governance update, common across all publicly traded companies, reflecting compliance with SEC regulations regarding shareholder meetings and voting outcomes. It does not provide specific industry-related insights beyond the company's operational compliance.

Comparison to Industry Standards

• The election of directors and ratification of auditors are standard corporate governance practices for publicly traded companies, aligning with industry norms.
• The high percentage of 'For' votes for the auditor ratification (over 99% of votes cast) is typical and indicates strong shareholder alignment on financial oversight, comparable to similar votes at other public companies.
• While the directors were elected, the 'Withheld' votes for directors (approximately 25% of votes cast for each director, excluding broker non-votes) are notable and could be higher than average for uncontested elections, warranting closer scrutiny in comparison to peer companies' director election results.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: The voting results confirm the composition of the board and the independent auditor, providing clarity on corporate governance and oversight.
• Management: The re-election of directors indicates continued shareholder support for the current strategic direction and leadership.

Next Steps

• The elected Class II Directors, Isaac Barchas and Jean-Jacques Bienaim, will serve until the Company's 2028 Annual Meeting of Stockholders.
• Ernst & Young LLP will serve as the independent registered public accounting firm for the fiscal year ending December 31, 2025.

Key Dates

Recommendation

Keywords

Immunome, IMNM, SEC filing, 8-K, annual meeting, stockholder vote, director election, corporate governance, independent auditor, Ernst & Young LLP, Nasdaq Capital Market